Vaxchora: A Single-Dose Oral Cholera Vaccine

Cabrera, Adriana; Lepage, Jayne E.; Sullivan, Karyn M.; Seed, Sheila M.

doi:10.1177/1060028017698162

Cited by 23 publications

(11 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For prevention, the FDA recently approved the first cholera vaccine, Vaxchora, composed of attenuated live bacteria, but the vaccine is currently only effective for V . cholerae serogroup 01 and, as a live agent, has the potential to cause disease itself, either in attenuated form in predisposed individuals or potentially upon reversion to a more virulent form [ 26 ]. In this regard, quality controls of live microbial agents as therapeutic agents can be challenging.…”

Section: Discussionmentioning

confidence: 99%

Neutralization of cholera toxin with nanoparticle decoys for treatment of cholera

Das

Angsantikul

et al. 2018

PLoS Negl Trop Dis

View full text Add to dashboard Cite

Diarrheal diseases are a major cause of morbidity and mortality worldwide. In many cases, antibiotic therapy is either ineffective or not recommended due to concerns about emergence of resistance. The pathogenesis of several of the most prevalent infections, including cholera and enteroxigenic Escherichia coli, is dominated by enterotoxins produced by lumen-dwelling pathogens before clearance by intestinal defenses. Toxins gain access to the host through critical host receptors, making these receptors attractive targets for alternative antimicrobial strategies that do not rely on conventional antibiotics. Here, we developed a new nanotechnology strategy as a countermeasure against cholera, one of the most important and prevalent toxin-mediated enteric infections. The key host receptor for cholera toxin, monosialotetrahexosylganglioside (GM1), was coated onto the surface of polymeric nanoparticles. The resulting GM1-polymer hybrid nanoparticles were shown to function as toxin decoys by selectively and stably binding cholera toxin, and neutralizing its actions on epithelial cells in vitro and in vivo. Furthermore, the GM1-coated nanoparticle decoys attenuated epithelial 3’,5’-cyclic adenosine monophosphate production and fluid responses to infection with live Vibrio cholera in cell culture and a murine infection model. Together, these studies illustrate that the new nanotechnology-based platform can be employed as a non-traditional antimicrobial strategy for the management of enteric infections with enterotoxin-producing pathogens.

show abstract

Section: Discussionmentioning

confidence: 99%

Neutralization of cholera toxin with nanoparticle decoys for treatment of cholera

Das

Angsantikul

et al. 2018

PLoS Negl Trop Dis

View full text Add to dashboard Cite

show abstract

“…One widely used WC strain vaccine is Dukoral (CTB-WC), which contains inactivated/dead V. cholerae O1 (El Tor and classical biotypes) with the addition of recombinant B subunits of CT (CTB) 12, 16, 30, 31 . The effectiveness of Dukoral is between 55% and 88% 17 , and it is intended for travelers but—owing to its short period of usability, high cost, and its requirements for cold-chain circulation—not for populations in endemic regions 9, 25 .…”

Section: Vaccinesmentioning

confidence: 99%

Combating Cholera

Hsueh

Waters

2019

F1000Res

View full text Add to dashboard Cite

Cholera infections caused by the gamma-proteobacterium Vibrio cholerae have ravaged human populations for centuries, and cholera pandemics have afflicted every corner of the globe. Fortunately, interventions such as oral rehydration therapy, antibiotics/antimicrobials, and vaccines have saved countless people afflicted with cholera, and new interventions such as probiotics and phage therapy are being developed as promising approaches to treat even more cholera infections. Although current therapies are mostly effective and can reduce disease transmission, cholera outbreaks remain deadly, as was seen during recent outbreaks in Haiti, Ethiopia, and Yemen. This is due to significant underlying political and socioeconomic complications, including shortages of vaccines and clean food and water and a lack of health surveillance. In this review, we highlight the strengths and weaknesses of current cholera therapies, discuss emerging technologies, and argue that a multi-pronged, flexible approach is needed to continue to reduce the worldwide burden of cholera.

show abstract

“…Shanchol ® (manufactured by Shantha Biotech in India) and Dukoral ® (manufactured by SBL Vaccines) are the two WHO prequalified oral cholera vaccines used against cholera 47 . In 2016, the WHO approved a single-dose live oral cholera vaccine, Vaxchora ® in the United States for adults aged 18-64 yr travelling to a cholera-endemic area 48 . Several live attenuated cholera vaccines that have the ability of providing long-term protection with a single dose are under development, of which none are expected to be marketed within the following few years.…”

Section: Fighting the Diseasementioning

confidence: 99%

Changing facades of Vibrio cholerae: An enigma in the epidemiology of cholera

et al. 2018

View full text Add to dashboard Cite

Cholera, caused by the Gram-negative bacterium Vibrio cholerae, has ravaged humanity from time immemorial. Although the disease can be treated using antibiotics along with administration of oral rehydration salts and controlled by good sanitation, cholera is known to have produced mayhems in ancient times when little was known about the pathogen. By the 21st century, ample information about the pathogen, its epidemiology, genetics, treatment and control strategies was revealed. However, there is still fear of cholera outbreaks in developing countries, especially in the wake of natural calamities. Studies have proved that the bacterium is mutating and evolving, out-competing all our efforts to treat the disease with previously used antibiotics and control with existing vaccines. In this review, the major scientific insights of cholera research are discussed. Considering the important role of biofilm formation in the V. cholerae life cycle, the vast availability of next-generation sequencing data of the pathogen and multi-omic approach, the review thrusts on the identification of suitable biofilm-inhibiting targets and the discovery of anti-biofilm drugs from nature to control the disease.

show abstract

Vaxchora: A Single-Dose Oral Cholera Vaccine

Cited by 23 publications

References 14 publications

Neutralization of cholera toxin with nanoparticle decoys for treatment of cholera

Neutralization of cholera toxin with nanoparticle decoys for treatment of cholera

Combating Cholera

Changing facades of Vibrio cholerae: An enigma in the epidemiology of cholera

Contact Info

Product

Resources

About